Amneal Pharmaceuticals (AMRX)
(Real Time Quote from BATS)
$8.65 USD
-0.05 (-0.58%)
Updated Oct 2, 2024 09:52 AM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
AMRX 8.65 -0.05(-0.58%)
Will AMRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AMRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRX
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
AMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Other News for AMRX
Amneal Pharmaceuticals price target raised by $2 at Truist, here's why
Amneal Pharmaceuticals (AMRX) Gets a Buy from Truist Financial
Amneal and Metsera collaborate to supply obesity and metabolic disease medicines
Amneal and Metsera Partner to Target Obesity Market
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases